An update on the use of indacaterol in patients with COPD
Therapeutic Advances in Respiratory Disease, 01/24/2011
Brienza NS et al. – Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long–acting bronchodilators is recommended as more effective and convenient than short–acting bronchodilators, because the long–acting agents provide greater bronchodilator efficacy and symptomatic relief, increased tolerance to exercise, and improved rate of exacerbations and quality of life test scores.



